Glaukos Corporation
GKOS
Positions held
Your positionsGKOS isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Glaukos Corporation is positioned well in the medical devices industry, focusing on innovative solutions for glaucoma treatment, which is a growing market due to increasing prevalence of eye diseases.
- Revenue increased by 23% compared to the prior quarter, reaching $186 million.
- Gross margin improved to 81.7%, up from 77.9% in the previous quarter.
- Despite revenue growth, Glaukos has faced significant operational challenges, reflected in its negative profit margins and high debt-to-equity ratio.
- The operating margin remains negative at -8.5%, indicating ongoing struggles to achieve profitability.
- The company's score indicates a 'Sell' signal with a score of -5.00, reflecting negative market sentiment.
Fundamentals
| Market cap | $9.51B | Enterprise value | $9.33B | Trailing P/E | — | Forward P/E | 308.06 |
| PEG | — | Price / book | 13.91 | Beta | 0.70 | Dividend yield | 0.00% |
| Revenue growth | 49.5% | Earnings growth | — | Gross margin | 79.1% | Operating margin | -8.5% |
| Profit margin | -30.7% | ROE | -26.0% | ROA | -5.2% | Debt / equity | 0.16 |
| Current ratio | 5.04 | Free cash flow | $15.46M | Analyst recommendation | strong_buy | Mean target | $198.69 |
| 52w high | $191.62 | 52w low | $73.16 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $186M | $151M | $143M | $134M | $124M | — |
| Op margin | -8.5% | -13.2% | -97.7% | -12.3% | -18.3% | — |
| Net income | -$18.4M | -$19.8M | -$134M | -$16.2M | -$19.7M | — |
| Gross margin | 81.7% | 77.9% | -1.1% | 78.4% | 78.3% | — |
| Gross profit | $152M | $117M | -$1.5M | $105M | $97.2M | — |
| Operating income | -$15.8M | -$19.9M | -$140M | -$16.4M | -$22.7M | — |
- Revenue +23% vs prior quarter ($186M vs $151M).
- Gross margin 81.7% (was 77.9% prior quarter).
- Operating margin expanded to -8.5%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $507M | $383M | $315M | $283M | — |
| Op margin | -39.3% | -28.2% | -39.3% | -36.2% | — |
| Net income | -$188M | -$146M | -$135M | -$99.2M | — |
| Gross margin | 55.7% | 75.5% | 76.0% | 75.6% | — |
| Gross profit | $283M | $289M | $239M | $214M | — |
| Operating income | -$200M | -$108M | -$124M | -$102M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Glaukos Advances Eye Care Portfolio with Three-Year Epioxa Trial Data and Licensing Deal
2026-10-08 · Will Three-Year Epioxa Data in Keratoconus Shift Glaukos' (GKOS) Corneal Portfolio Narrative?
2026-10-08 · Glaukos, RevOpsis Therapeutics Enter Exclusive License Agreement for Retinal Biologics
2026-10-07 · Glaukos Epioxa Phase 3 Extension Shows Sustained Efficacy, Favorable Safety at Three Years
2026-10-07 · Glaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes in Keratoconus
2026-10-07 · Can ISRG's Single-Port Platform Become the Next Billion-Dollar Franchise?
2026-10-07 · Glaukos to Release Third Quarter 2026 Financial Results after Market Close on October 28
2026-09-24 · Here's Why You Should Retain Glaukos Stock in Your Portfolio for Now
2026-09-23 · Glaukos (GKOS) Stock Looks Fully Priced Against Its Sales Growth Story
2026-09-23 · Glaukos (GKOS), Why Is It Back In The Spotlight?
Price (daily)
Full chart · RSI · MACD · patterns